Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer.
复制标题
每周一次紫杉醇作为 S-1 难治性晚期胃癌二线治疗的 II 期研究。
DOI：
10.1245/s10434-009-0361-4
复制
发表时间：
2009
影响因子：
2
通讯作者：
Y. Ichikawa
中科院分区：
文献类型：
--
作者：
G. Matsuda;C. Kunisaki;H. Makino;Michiko Fukahori;J. Kimura;Tsutomu Sato;T. Oshima;Y. Nagano;Shoichi Fuii;R. Takagawa;T. Kosaka;H. A. Ono;H. Akiyama;Y. Ichikawa
背景
我们回顾性评估了每周紫杉醇治疗作为二线治疗对 S-1 耐药的晚期胃癌患者的疗效。
患者和方法
总共有 33 名患者在第 1、8 和 15 天接受静脉注射紫杉醇 (80 mg m(-2))，作为 4 周周期的一部分。
结果
8 名患者显示出部分缓解，11 名患者显示疾病稳定，14 名患者显示疾病进展。总共进行了 171 门课程（平均值=5.2；范围=3-16）。 13例随后接受了三线治疗。从二线治疗开始，中位生存时间和进展时间分别为 8.0 个月和 4.2 个月。最常见的血液学毒性是白细胞减少症和中性粒细胞减少症。非血液学毒性通常为轻度至中度且可控。
结论
这项研究显示了晚期胃癌患者良好的治疗结果。然而，有必要在更大的人群中确认紫杉醇治疗 S-1 难治性晚期胃癌的优势。
BACKGROUND
We retrospectively evaluated the efficacy of weekly paclitaxel therapy as second-line treatment for patients with advanced gastric cancer that was refractory to S-1.
PATIENTS AND METHODS
In total, 33 patients received intravenous paclitaxel (80 mg m(-2)) on days 1, 8 and 15 as part of a 4-week cycle.
RESULTS
Eight patients showed a partial response, 11 showed stable disease and 14 showed disease progression. In total, 171 courses (mean=5.2; range=3-16) were administered. Thirteen cases subsequently underwent third-line treatment. The median survival time and time to progression from the time of second-line treatment was 8.0 months and 4.2 months, respectively. The most common haematological toxicities were leukopenia and neutropenia. Non-haematological toxicities were generally mild to moderate and controllable.
CONCLUSION
This study showed favourable therapeutic outcomes for advanced gastric cancer patients. However, it will be necessary to confirm the advantages of paclitaxel treatment for S-1-refractory advanced gastric cancer in a larger population.
影响因子：
158.5
作者：
Sakuramoto, Shinichi;Sasako, Mitsuru;Arai, Kuniyoshi
通讯作者：
Arai, Kuniyoshi
影响因子：
51.1
作者：
Koizumi, Wasaburo;Narahara, Hiroyuki;Takeuchi, Masahiro
通讯作者：
Takeuchi, Masahiro
在晚期胃癌患者中每周使用紫杉醇和多西氟尿苷的联合 I 期研究。
DOI：
--
发表时间：
2005
期刊：
Anticancer Res. 25
影响因子：
--
作者：
Takeyoshi I;Makita F;Tanahashi Y;Yokomori T;Iwazaki S;Kawashima Y;Iwanami K;Yamada T;Kawate S;Hamada K;Sunose Y;Yoshida M;Horiguchi J;Iesato H;Kobayashi M;Morishita Y.
通讯作者：
Morishita Y.